Lu Lu

Lu Lu

Auto-generated profile, based on publicly available information

Lu Lu

Department of Neurology West China Hospital of Sichuan University Chengdu China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ZHZhen Hong
Zhen Hong
NLNian Li
Nian Li
DLDajiang Li
Dajiang Li
JLJunhua Li
Junhua Li
BLBing Li
Bing Li
DZDong Zhou
Dong Zhou
Disasters and pandemics pose unique challenges to health care delivery. As health care resources continue to be stretched due to the increasing burden of the coronavirus disease (COVID-19) pandemic, telemedicine, including tele-education, may be an effective way to rationally allocate medical resources. During the COVID-19 pandemic, a multimodal telemedicine network in Sichuan Province in Western China was activated immediately after the first outbreak in January 2020. The network synergizes a newly established 5G service, a smartphone app, and an existing telemedicine system. Telemedicine was demonstrated to be feasible, acceptable, and effective in Western China, and allowed for significant improvements in health care outcomes. The success of telemedicine here may be a useful reference for other parts of the world.

2 May 2020 in Epilepsia
Verified
Journal Article
Open access
PDF file
LLLu Lu
Lu Lu
WXWeixi Xiong
Weixi Xiong
DLDan Liu
Dan Liu
JLJing Liu
Jing Liu
DYDan Yang
Dan Yang
DZDong Zhou
Dong Zhou
Our aim was to clarify the incidence and risk of acute symptomatic seizures in people with coronavirus disease 2019 (COVID‐19). This multicenter retrospective study enrolled people with COVID‐19 from January 18 to February 18, 2020 at 42 government‐designated hospitals in Hubei province, the epicenter of the epidemic in China; Sichuan province; and Chongqing municipality. Data were collected from medical records by 11 neurologists using a standard case report form. A total of 304 people were enrolled, of whom 108 had a severe condition. None in this cohort had a known history of epilepsy. Neither acute symptomatic seizures nor status epilepticus was observed. Two people had seizurelike symptoms during hospitalization due to acute stress reaction and hypocalcemia, and 84 (27%) had brain insults or metabolic imbalances during the disease course known to increase the risk of seizures. There was no evidence suggesting an additional risk of acute symptomatic seizures in people with COVID‐19. Neither the virus nor potential risk factors for seizures seem to be significant risks for the occurrence of acute symptomatic seizures in COVID‐19.

15 September 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
WXWeixi Xiong
Weixi Xiong
JMJie Mu
Jie Mu
JGJian Guo
Jian Guo
LLLu Lu
Lu Lu
DLDan Liu
Dan Liu
DZDong Zhou
Dong Zhou
Objective To investigate new-onset neurologic impairments associated with coronavirus disease 2019 (COVID-19). Methods A retrospective multicenter cohort study was conducted between January 18 and March 20, 2020, including people with confirmed COVID-19 from 56 hospitals officially designated in 3 Chinese regions; data were extracted from medical records. New-onset neurologic events as assessed by neurology consultants based on manifestations, clinical examination, and investigations were noted, in which critical events included disorders of consciousness, stroke, CNS infection, seizures, and status epilepticus. Results We enrolled 917 people with average age 48.7 years and 55% were male. The frequency of new-onset critical neurologic events was 3.5% (32/917) overall and 9.4% (30/319) among those with severe or critical COVID-19. These were impaired consciousness (n = 25) or stroke (n = 10). The risk of critical neurologic events was highly associated with age above 60 years and previous history of neurologic conditions. Noncritical events were seen in fewer than 1% (7/917), including muscle cramp, unexplained headache, occipital neuralgia, tic, and tremor. Brain CT in 28 people led to new findings in 9. Findings from lumbar puncture in 3 with suspected CNS infection, unexplained headache, or severe occipital neuralgia were unremarkable. Conclusions People with COVID-19 aged over 60 and with neurologic comorbidities were at higher risk of developing critical neurologic impairment, mainly impaired consciousness and cerebrovascular accidents. Brain CT should be considered when new-onset brain injury is suspected, especially in people under sedation or showing an unexplained decline in consciousness. Evidence of direct acute insult of severe acute respiratory syndrome coronavirus 2 to the CNS is lacking.

29 March 2021 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
LLLu Lu
Lu Lu
WXWeixi Xiong
Weixi Xiong
JMJie Mu
Jie Mu
QZQi Zhang
Qi Zhang
HZHesheng Zhang
Hesheng Zhang
DZDong Zhou
Dong Zhou

21 November 2021 in Epilepsia
Verified
Journal Article
Open access
PDF file
LLLu Lu
Lu Lu
QZQi Zhang
Qi Zhang
JXJing Xiao
Jing Xiao
YZYingying Zhang
Yingying Zhang
WPWei Peng
Wei Peng
WXWeixi Xiong
Weixi Xiong
Summary: Objective: This study was undertaken to investigate the COVID‐19 vaccine uptake rate and possible postvaccination effects in adults with epilepsy.Methods: We invited adults with epilepsy attending three centers in China from July 24 to August 31, 2021 to participate in this study. We also asked age‐ and sex‐matched controls among people attending for other chronic neuropsychiatric conditions and healthy controls accompanying people with illness attending the hospitals to participate. We excluded people who, under the national guidelines, had evident contradictions to vaccination. Participants were interviewed face‐to‐face using questionnaires. Vaccine uptake and postvaccine adverse events among the people with epilepsy were compared with those with neuropsychiatric conditions and controls. We also compared the willingness and reasons for hesitancy among unvaccinated participants.Results: We enrolled 981 people, of whom 491 had epilepsy, 217 had other neuropsychiatric conditions, and 273 were controls. Forty‐two percent of those with epilepsy had had the first dose of a vaccine, compared with 93% of controls and 84% of the people with neuropsychiatric conditions (p < .0001). The majority (93.8%) of those immunized had inactivated vaccines. Among the unvaccinated people with epilepsy, 59.6% were willing to have the vaccine. Their main reasons for hesitation were potential adverse effects (53.3%) and concerns about losing seizure control (47.0%). The incidence of adverse events in the epilepsy group was similar to controls. Nineteen people with epilepsy reported an increase in seizure frequency. No episode of status epilepticus or prolonged seizures was reported. Two controls had their first‐ever seizure, which was unlikely related to the vaccine.Significance: The vaccine uptake rate in people with epilepsy was lower than in their same‐age controls. The postvaccination effect was no higher than in controls. We found no evidence suggesting worsening seizures after vaccination. Measurement and education focused on increasing the vaccination rate in epilepsy are warranted.

1 August 2019 in Epilepsy Research
Verified
Journal Article
Closed access
WXWeixi Xiong
Weixi Xiong
LLLu Lu
Lu Lu
YZYingying Zhang
Yingying Zhang
YXYingfeng Xiao
Yingfeng Xiao
HGHui Gao
Hui Gao
DZDong Zhou
Dong Zhou